pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Drugs
by stage
  • Marketed
  • Phase 3
  • Phase 2
  • Phase 1
  • Preclinical
browse
  • Most catalysts
  • Recently active
  • All drugs →
  • Companies
  • Patent cliff
Calendar
what
  • Trial readouts
  • PDUFA dates
  • Approvals
  • Earnings
when
  • Upcoming
  • Month grid
  • Recently passed
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
  • Drugs
  • Calendar
  • Companies
Hubs
  • Topics
  • Patent cliff
  • Publications
  • Readouts
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
Endpoints·49m ago·1 min read
save

Sanofi may seek higher European drug prices, not withhold launches, under Trump deal

While some of Europe’s biggest drugmakers have warned that President Donald Trump’s pricing policies could leave European patients waiting longer for new medicines, Sanofi is taking a different approach. ...

Oct 30, 2026·read at Endpoints ↗

October 30, 2026 12:16 PM EDT Pharma Sanofi may seek high­er Eu­ro­pean drug prices, not with­hold launch­es, un­der Trump deal Maggie Fick Pharma reporter While some of Eu­rope’s biggest drug­mak­ers have warned that Pres­i­dent Don­ald Trump’s pric­ing poli­cies could leave Eu­ro­pean pa­tients wait­ing … Sign up to read this article for free. Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox. SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER

source

Reporting by Endpoints.

read at Endpoints ↗
78 words · retrieved 29m ago
sharex / twitterlinkedin

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?

companies & drugs in this story

companies
Sanofi3

related stories

  • May 7Official leading CDC’s cruise ship program retiresSTAT
  • May 7STAT+: More political interference at the FDA?STAT
  • May 7STAT+: Pharmalittle: We’re reading about Sanofi and an FDA voucher, FDA rethinking a rejection, and moreSTAT
  • May 6Trump administration’s drug strategy is at odds with recent actions on funding, policySTAT
  • May 6STAT+: Administration report on most favored nation drug pricing raises new details — and questionsSTAT